TY - JOUR
T1 - Characterization of DLBCL with a PMBL gene expression signature
AU - Duns, Gerben
AU - Viganò, Elena
AU - Ennishi, Daisuke
AU - Sarkozy, Clementine
AU - Hung, Stacy S.
AU - Chavez, Elizabeth
AU - Takata, Katsuyoshi
AU - Rushton, Christopher
AU - Jiang, Aixiang
AU - Ben-Neriah, Susana
AU - Woolcock, Bruce W.
AU - Slack, Graham W.
AU - Hsi, Eric D.
AU - Craig, Jeffrey W.
AU - Hilton, Laura K.
AU - Shah, Sohrab P.
AU - Farinha, Pedro
AU - Mottok, Anja
AU - Gascoyne, Randy D.
AU - Morin, Ryan D.
AU - Savage, Kerry J.
AU - Scott, David W.
AU - Steidl, Christian
N1 - Funding Information:
This study was supported by Program Project Grant funding from the Terry Fox Research Institute (grant 1061), Large Scale Applied Research Project funding from Genome Canada (grant 13124; C.S.), Genome British Columbia (grant 271LYM; C.S.), Canadian Institutes of Health Research (CIHR; grant GP1-155873; C.S.) and the British Columbia Cancer Foundation, and a Foundation Grant from CIHR. C.S. is supported by the Michael Smith Foundation for Health Research, Career Investigator Award. D.W.S. is supported by a Michael Smith Foundation for Health Research, Health Professional Investigator Award. The Centre for Lymphoid Cancer acknowledges the support from the BC Cancer Foundation. E.V. was supported by a fellowship from the Michael Smith Foundation for Health Research.
Funding Information:
Conflict-of-interest disclosure: C. Steidl has performed consultancy for Seattle Genetics, Curis, Inc, Roche, AbbVie, AstraZeneca, Juno Therapeutics, and Bayer and received research funding from Bristol-Myers Squibb, Epizyme, and Trillium Therapeutics, Inc. C. Steidl, D.W.S., and A.M. are coinventors on a patent (“Method for determining lymphoma type”) using NanoString technology. D.W.S. has performed consultancy for AbbVie, AstraZeneca, Celgene, and Janssen and received research funding from Janssen and NanoString Technologies. K.J.S. reports honoraria from Seattle Genetics, Bristol-Myers Squibb, Merck, AbbVie, AstraZeneca, and Gilead; consultancy for Servier; and institutional funds from Roche. J.W.C. has received honoraria from Seattle Genetics and Takeda Pharmaceuticals. E.D.H. has performed consultancy for Cytomx, Seattle Genetics, and Mitenyi and received research funding from AbbVie and Eli Lilly. S.P.S. is a shareholder in Canexia Health Inc. The remaining authors declare no competing financial interests.
Publisher Copyright:
© 2021 American Society of Hematology
PY - 2021/7/15
Y1 - 2021/7/15
N2 - Primary mediastinal large B-cell lymphoma (PMBL) is a type of aggressive B-cell lymphoma that typically affects young adults, characterized by presence of a bulky anterior mediastinal mass. Lymphomas with gene expression features of PMBL have been described in nonmediastinal sites, raising questions about how these tumors should be classified. Here, we investigated whether these nonmediastinal lymphomas are indeed PMBLs or instead represent a distinct group within diffuse large B-cell lymphoma (DLBCL). From a cohort of 325 de novo DLBCL cases, we identified tumors from patients without evidence of anterior mediastinal involvement that expressed a PMBL expression signature (nm-PMBLsig+; n = 16; 5%). A majority of these tumors expressed MAL and CD23, proteins typically observed in bona fide PMBL (bf-PMBL). Evaluation of clinical features of nm-PMBLsig+ cases revealed close associations with DLBCL, and a majority displayed a germinal center B cell–like cell of origin (GCB). In contrast to patients with bf-PMBL, patients with nm-PMBLsig+ presented at an older age and did not show pleural disease, and bone/bone marrow involvement was observed in 3 cases. However, although clinically distinct from bf-PMBL, nm-PMBLsig+ tumors resembled bf-PMBL at the molecular level, with upregulation of immune response, JAK-STAT, and NF-κB signatures. Mutational analysis revealed frequent somatic gene mutations in SOCS1, IL4R, ITPKB, and STAT6, as well as CD83 and BIRC3, with the latter genes significantly more frequently affected than in GCB DLBCL or bf-PMBL. Our data establish nm-PMBLsig+ lymphomas as a group within DLBCL with distinct phenotypic and genetic features. These findings may have implications for gene expression– and mutation-based subtyping of aggressive B-cell lymphomas and related targeted therapies.
AB - Primary mediastinal large B-cell lymphoma (PMBL) is a type of aggressive B-cell lymphoma that typically affects young adults, characterized by presence of a bulky anterior mediastinal mass. Lymphomas with gene expression features of PMBL have been described in nonmediastinal sites, raising questions about how these tumors should be classified. Here, we investigated whether these nonmediastinal lymphomas are indeed PMBLs or instead represent a distinct group within diffuse large B-cell lymphoma (DLBCL). From a cohort of 325 de novo DLBCL cases, we identified tumors from patients without evidence of anterior mediastinal involvement that expressed a PMBL expression signature (nm-PMBLsig+; n = 16; 5%). A majority of these tumors expressed MAL and CD23, proteins typically observed in bona fide PMBL (bf-PMBL). Evaluation of clinical features of nm-PMBLsig+ cases revealed close associations with DLBCL, and a majority displayed a germinal center B cell–like cell of origin (GCB). In contrast to patients with bf-PMBL, patients with nm-PMBLsig+ presented at an older age and did not show pleural disease, and bone/bone marrow involvement was observed in 3 cases. However, although clinically distinct from bf-PMBL, nm-PMBLsig+ tumors resembled bf-PMBL at the molecular level, with upregulation of immune response, JAK-STAT, and NF-κB signatures. Mutational analysis revealed frequent somatic gene mutations in SOCS1, IL4R, ITPKB, and STAT6, as well as CD83 and BIRC3, with the latter genes significantly more frequently affected than in GCB DLBCL or bf-PMBL. Our data establish nm-PMBLsig+ lymphomas as a group within DLBCL with distinct phenotypic and genetic features. These findings may have implications for gene expression– and mutation-based subtyping of aggressive B-cell lymphomas and related targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=85110101797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110101797&partnerID=8YFLogxK
U2 - 10.1182/blood.2020007683
DO - 10.1182/blood.2020007683
M3 - Article
C2 - 33684939
AN - SCOPUS:85110101797
SN - 0006-4971
VL - 138
SP - 136
EP - 148
JO - Blood
JF - Blood
IS - 2
ER -